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Abstract
Background: In the elderly the diagnosis of chronic heart failure is often challenging and the availability of
echocardiography can be limited. Plasma levels of NT-proBNP are valuable tools to diagnose patients with heart
failure. However, the performance of this biomarker to detect cardiac abnormalities in the very elderly remains
unclear. The aims of this study were to investigate the relation between NT-proBNP and cardiac abnormalities and
to evaluate the use of NT-proBNP to exclude structural and functional cardiac abnormalities in a community-based
sample of “well-functioning” nonagenarians.
Methods: A diagnostic cross-sectional study embedded within the Leiden 85-plus Study in the municipality of
Leiden, the Netherlands. Plasma NT-proBNP levels were measured and 2-dimensional echocardiography was
performed in a subgroup of 80 well-functioning nonagenarians. Linear regression analysis was used to explore the
relation between NT-proBNP and cardiac abnormalities and ROC curve analysis was used to assess the performance
of NT-proBNP to exclude cardiac abnormalities. The upper limit of the lowest tertile of NT-proBNP was used as a
cut-off value.
Results: NT-proBNP levels were associated with abnormal left ventricular (LV) dimensions, LV systolic and diastolic
function, left atrial enlargement and valvular heart disease. LV mass, E/A ratio and degree of aortic regurgitation
were identified as independent predictors of NT-proBNP. NT-proBNP levels were higher with greater number of
echocardiographic abnormalities (P < 0.001). A cut-off level of 269.5 pg/mL identified patients with abnormal LV
dimensions or depressed LV systolic function (sensitivity 85%, negative predictive value (NPV) 77%, area under the
curve 0.75 (95% CI 0.64-0.85)). In addition, high NPV were found for LV systolic dysfunction, left atrial enlargement,
severe valvular heart disease and pulmonary hypertension. The test performance of NT-proBNP to exclude any
echocardiographic abnormality showed a sensitivity of 82% and a NPV of 65%.
Conclusions: In this convenience sample of well-functioning nonagenarians NT-proBNP was related to a wide
variety of functional and structural echocardiographic abnormalities. Moreover, NT-proBNP could be used to
exclude echocardiographic abnormalities in well-functioning nonagenarians and might be used to indicate who
needs to be referred for further cardiovascular examination.
Background
Chronic heart failure is becoming more frequent in our
aging societies. The prevalence of heart failure increases
with age from 0.7% in people aged 55-64 years to 13.0%
in those aged 75-84 years [1]. In the elderly, the diagno-
sis of chronic heart failure is often challenging when
there are multiple comorbidities and many other possi-
ble causes for dyspnoea, fatigue or peripheral oedema
can be present. Echocardiography is currently the diag-
nostic test of first choice for identifying structural and
functional cardiac abnormalities. However, its availability
for the very elderly can be limited, so there is the likeli-
hood of a considerable over- and underdiagnosis of
heart failure [2,3]. This emphasises the need for a simple
test to identify patients at risk.
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NT-proBNP (N-terminal pro-brain natriuretic peptide)
are valuable tools to diagnose patients with heart failure.
These measures have shown to provide prognostic infor-
mation of mortality and major cardiovascular events, not
only in patients with chronic heart failure or coronary
artery disease but also in the general population, and
this can improve patient management [4-8]. In addition,
the measurement of these natriuretic peptides has been
proposed in screening for left ventricular (LV) dysfunc-
tion in high-risk patients, such as the elderly [9,10].
However, multiple factors are known to influence the
circulating levels of natriuretic peptides. The prevalence
of possible influencing factors, like renal dysfunction
and anemia, increases in the very elderly [11,12]. An
understanding of these is a prerequisite for the optimal
use of these levels as a tool for diagnosing cardiac dys-
function in the community [13]. In the Leiden 85-plus
Study a strong and specific correlation between plasma
NT-proBNP and various cardiac diagnoses, like atrial
fibrillation and myocardial infarction, was found in non-
agenarians [14]. However, the performance of this bio-
marker to detect structural and functional cardiac
abnormalities in this subgroup of subjects remains
unclear. Therefore, the aims of the present study were
first, to study the relation between NT-proBNP levels
and structural and functional cardiac abnormalities in a
convenience sample of 80 “well-functioning” nonagenar-
ians; second, to evaluate the use of NT-proBNP levels to
exclude structural and functional cardiac abnormalities
in this age group.
Methods
Study Population
The Leiden 85-plus Study is an observational, prospec-
tive population-based study of inhabitants of the city of
Leiden, The Netherlands. The study design and charac-
teristics of the cohort have been described in detail [15].
In brief, between September 1997 and September 1999
all 705 members of the 1912-1914 birth cohort in the
city of Leiden were asked to participate in the month
after their 85
th birthday. There were no exclusion cri-
teria regarding health status or demographic characteris-
tics. At baseline and yearly up to the age of 90, the
participants were visited at their place of residence. For
the current study, a convenience sample of 82 partici-
pants was invited for echocardiography. The study nurse
invited those participants who were physically able to
visit the research centre and whose cognitive function
allowed them to undergo various technical investiga-
tions. All but one underwent echocardiography. All par-
ticipants in the study gave informed consent and the
Medical Ethics Commission of the Leiden University
Medical Centre approved the study.
Functional and Clinical Characteristics
Evaluation of the functional status of participants
included measures of cognitive function, subjective well-
being, disability and depressive symptoms. Cognitive
function was assessed by the Mini-Mental State Exami-
nation (MMSE), with scores ranging from 0 to 30 points
(optimal) [16]. Subjective well-being was tested with a
visual analogue scale (CANTRIL) in those with MMSE
>18 points, with scores ranging from 0 to 10 (optimal)
[16]. Disability was assessed on the Groningen Activity
Restriction Scale (GARS), which is a combination of
nine items relating to activities of daily living (ADLs)
and nine items relating to instrumental ADLs: scores
range from 18 (totally independent) to 72 points (totally
dependent) [16]. Depressive symptoms were measured
in those with MMSE >18 points, using the 15-item
Geriatric Depression Scale (GDS-15), with scores ran-
ging from 0 (optimal) to 15 points [16]. Each partici-
pant’s general practitioner (or, if applicable, his/her
nursing home physician) was interviewed annually about
the patient’s medical history, using standardised ques-
tionnaires including questions on present and past car-
diovascular and non-cardiovascular morbidities. Specific
cardiac diagnoses were defined as the presence of a
medical history of myocardial infarction, angina pectoris,
arrhythmias or heart failure, or an electrocardiogram
(ECG) at age 90 years revealing a prior myocardial
infarction (Minnesota Code 1-1 or 1-2, excluding 1-2-8),
atrial fibrillation (Minnesota Code 8-3-1) or LV hyper-
trophy (Minnesota Code 310, 330 or 340) [17]. Other
vascular morbidity was defined as the presence of a
diagnosed noncardiac vascular morbidity including
stroke and peripheral arterial disease. Non-cardiovascu-
lar morbidity was defined as the presence of a medical
history of Parkinson’s disease, chronic obstructive pul-
monary disease, arthroses (including rheumatoid arthri-
tis and polymyalgia rheumatica), malignancies and/or
hip fracture.
Plasma Levels of NT-proBNP at Age 90
Blood samples were taken within the month after every
participant’s 90th birthday, and were kept frozen at
-80°C. In 2006 citrated plasma levels of NT-proBNP
were measured in one batch using the NT-proBNP
assay of Roche Diagnostics (Mannheim, Germany) on
a Roche Modular E-170 automated immunoanalyser.
The within-run coefficient of variation was less than
2% and total variation was less than 6% at all levels
measured (400-13500 pg/mL).
Echocardiography
All patients were imaged between January and Septem-
ber 2004, in stable hemodynamic conditions. In the
majority of the patients, transthoracic echocardiography
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patients who underwent echocardiography at a different
day, no cardiac events were recorded between the two
tests. The echocardiographic evaluation was performed
by one experienced observer blinded to the NT-proBNP
levels.
All patients were imaged in the left lateral decubitus
position using a commercially available system (Vingmed
system/Vivid Seven, General Electric-Vingmed, Milwau-
kee, WI, USA) equipped with a 3.5-MHz transducer.
Echocardiographic images were acquired at a depth of
16 cm in the parasternal and apical views. Left ventricular
(LV) dimensions were measured from M-mode images at
the parasternal long-axis view. The LV ejection fraction
was derived using the Teichholz formula [18]. Left ventri-
cular diameters were indexed to the body surface area.
Left ventricular mass was measured according to the for-
mula proposed by Devereux et al. and indexed to the
body surface area [19]. Left ventricular hypertrophy was
defined by an LV mass index >149 g/m
2 in men and
>122 g/m
2 for women [20].
Left ventricular diastolic function was assessed from
pulsed-wave Doppler recordings of the transmitral
inflow, measuring the early (E) and atrial (A) wave peak
velocities and the E/A ratio [21]. In addition, left atrial
dimensions were measured as a morphologic expression
of diastolic function [22]. Left atrial anteroposterior dia-
meter was measured from M-mode images at the para-
sternal long-axis view and left atrial volume was derived
according to the cube formula and indexed to body sur-
face area [20].
The function of the mitral, aortic and tricuspid valves
were evaluated with color Doppler echocardiography
after optimising the gain and Nyquist limit. Standard
continuous and pulsed-wave Doppler recordings were
acquired. Stenotic and regurgitant valve diseases were
evaluated according to semiquantitative and quantitative
methods recommended by the American Society of
Echocardiography [23]. When tricuspid regurgitation
was present, pulmonary artery pressure was estimated
using the modified Bernoulli equation [21].
Confounding Variables
As previously described, plasma levels of NT-proBNP
are influenced by gender, body mass index (BMI), renal
dysfunction, anemia and medications for heart failure
[11,12,24,25]. Therefore, these parameters were defined
as possible confounding variables. BMI at age 90 years
was assessed by measuring the subject’sh e i g h ta n d
weight. Renal function was estimated using the criteria
of the Modification of Diet in Renal Disease Study
Group [26]. Anemia was defined as hemoglobin levels
<7.5 mmol/L for women and <8.1 mmol/L for men.
Data on relevant cardiovascular medications were
gathered from each participant’s pharmacist, including
any use of diuretics, beta-blockers, angiotensin convert-
ing enzyme inhibitors, angiotensin II receptor blockers
or digoxin.
Data Analysis
Echocardiographic parameters were compared between
tertiles of NT-proBNP using the Jonckheere-Terpstra test
or the Chi-squared test with linear-by-linear association.
Levels of NT-proBNP were log-transformed and the
association with echocardiographic parameters was
explored further using linear regression analysis cor-
rected for confounding variables. Analysis of variance
(ANOVA) testing was used to compare the mean
LogNT-proBNP values between different categories of
increasing number of cardiac abnormalities.
The performance of NT-proBNP to exclude structural
and functional abnormalities was assessed using receiver
operating characteristic (ROC) curve analysis. The upper
limit of the lowest tertile was used as a cut-off value for
NT-proBNP and the sensitivity, specificity, negative pre-
dictive value (NPV) and positive predictive value (PPV)
were calculated. The highest cut-off value with an NPV
of 100% was reported. Data analyses were performed
using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
The initial cohort consisted of 599 participants at age
85 years. A total of 276 individuals survived up to the
age of 90 years. Levels of NT-proBNP were determined
in 274 participants. Both echocardiographic data and
NT-proBNP levels were available in 80 well-functioning
subjects. The prevalence of cardiovascular and non-
cardiovascular comorbidities was similar for patients with
and without echocardiography (Table 1). There was a dif-
ference in NT-proBNP levels between both groups (P >
0.05), but the upper limit of the lowest tertile was in the
same range (269.5 pg/mL vs 306.7 pg/mL).
Most patients showed normal LV end-diastolic dia-
meter (n = 69, 86%) and had a preserved LV ejection
fraction (n = 73, 91%). According to current criteria, LV
hypertrophy was present in 35% (n = 9) of men and
45% (n = 23) of women (Table 2).
Patients in the highest NT-proBNP tertile showed sig-
nificantly larger LV dimensions, higher values of LV
mass and a higher E/A ratio together with a larger left
atrial volume (Table 3). In addition, a higher prevalence
of significant mitral and aortic valve regurgitation
was observed in patients in the highest NT-proBNP
tertile, together with higher values of pulmonary artery
pressure.
Linear regression analyses with LogNT-proBNP as the
dependent variable and all echocardiographic parameters
as independent variables showed that LV mass, E/A
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pendent predictors of NT-proBNP after adjusting for
confounding variables (Table 3). Two multivariate
regression models were used to evaluate the indepen-
dent determinants of NT-proBNP levels: one including
pulmonary artery pressure and another one without.
The mean LogNT-proBNP was higher with greater
number of echocardiographic abnormalities (ANOVA,
P < 0.001) (Figure 1). Back transformation yielded the
following NT-proBNP levels: 238.2 pg/mL for a normal
echocardiographic result, 362.2 pg/mL for patients with
one echocardiographic abnormality, 527.2 pg/mL with
two and 833.7 pg/mL for patients with three or more.
Because NT-proBNP levels did not differ between men
and women (501.1 pg/mL (IQR 211.3-1468.3 pg/mL) and
349.5 pg/mL (IQR 214.9-682.5 pg/mL) respectively
(Mann-Whitney, P = 0.14)) and gender was no indepen-
dent predictor of NT-proBNP in the linear regression
analysis (P = 0.88), no gender-specific cut-off values were
used (Table 4). The prespecified NT-proBNP cut-off
value of 269.5 pg/mL identified LV dilatation, hypertro-
phy or systolic dysfunction with sensitivity, specificity,
PPV and NPV of 84%, 48%, 59% and 77%, respectively.
By reducing the cut-off value to 130 pg/mL, the NPV
increased to 100%. The prespecified cut-off value was
able to exclude an EF < 50 with an NPV of 92%.
To identify left atrial enlargement, severe valvular
heart disease and pulmonary hypertension, the prespeci-
fied cut-off value yielded a high sensitivity and NPV but
low specificity and PPV. An NT-proBNP cut-off value
Table 1 Sociodemographic, Functional and Clinical Characteristics of Participants with and without Echocardiography
at Age 90 Years
Echocardiographic examination
Yes (n = 80) No (n = 194)
n (%) P*
Sociodemographic characteristics
Male 26 (33) 50 (26) 0.28
Institutionalized 17 (21) 87 (45) <0.001
Education ≤ 6 years primary school 38 (48) 132 (68) 0.002
Income ≤ 750€ 34 (43) 105 (54) 0.09
Functional characteristics
Cognitive impairment (MMSE ≤ 18) 0 (0) 72 (38) <0.001
Poor well-being (CANTRIL < 7) 16 (20) 35 (29) 0.14
Dependent in daily living (GARS ≥ 56) 4 (5) 64 (34) <0.001
Depression (GDS-15 ≥ 5) 11 (14) 37 (31) 0.003
Clinical characteristics
Cardiovascular morbidity 48 (60) 132 (68) 0.22
Specific cardiac diagnoses
a 47 (59) 120 (62) 0.63
Atrial fibrillation on ECG 8 (10.0) 25 (13) 0.49
Diagnosis of heart failure 20 (25) 39 (21) 0.43
Other vascular morbidity
b 11 (14) 33 (18) 0.45
Cardiovascular risk factors
Hypertension 47 (59) 104 (55) 0.58
Diabetes mellitus type II 10 (13) 35 (21) 0.12
Non-cardiovascular morbidity
c 49 (61) 126 (65) 0.56
BMI > 25 kg/m
2 50 (65) 101 (64) 0.88
GFR < 60 mL/min/1.73 m
2 43 (54) 100 (52) 0.74
Anemia
d 11 (15) 51 (28) 0.014
Cardiovascular medication
e 34 (43) 97 (50) 0.26
NT-proBNP in pg/mL (median, IQR) 389.5 (220.7-779.1) 471.9 (252.8-1655.3) 0.10‡
aIncluding a history of myocardial infarction (clinical or by ECG), angina pectoris, arrhythmias, heart failure and ECG with atrial fibrillation or left ventricular
hypertrophy.
bIncluding a history of stroke and peripheral vascular disease.
cIncluding a history of Parkinson’s disease, chronic obstructive pulmonary disease, arthritis (including arthrosis, rheumatoid arthritis and polymyalgia rheumatica),
malignancies or hip fracture.
dHemoglobin < 7.5 mmol/L for women, <8.1 mmol/L for men.
eIncluding any use of diuretics, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers or digoxin.
* Independent Student’s t-test; ‡, Mann-Whitney U test; IQR, inter quartile range.
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heart disease.
The test performance of NT-proBNP to exclude
severe valvular heart disease and/or LV systolic dys-
function showed a sensitivity of 84% and a NPV of
85%. In addition, the diagnostic accuracy of NT-
proBNP to exclude any echocardiographic abnormality
(n = 50) was calculated. If only the participants with
an NT-proBNP level >269.5 pg/mL (n = 54) would be
referred for echocardiography, 9 cases would be missed
(18%) and 13 negative echoes (0 abnormalities) would
be done (43%).
Discussion
In this convenience sample of well-functioning nonagen-
arians we showed NT-proBNP is not just an indicator of
increased cardiac pressure but is related to a wide vari-
ety of functional and structural echocardiographic
abnormalities. This confirms the hypothesis that
natriuretic peptides could possibly be used to identify
‘pancardiac’ d a m a g e ,e v e nw h e ni ti ss i l e n t[ 2 7 ] .I na
previous study in this cohort NT-proBNP was found to
be a good predictor for both cardiovascular and noncar-
diovascular mortality, both in elderly with and without
specific cardiac diagnoses. This indicated elevated
plasma NT-proBNP levels possibly reflect unknown car-
diac morbidity or imminent heart failure [14]. In this
convenience sample 18 of 33 patients (56%) without
specific cardiac diagnoses had one or more echocardio-
graphic abnormality. Moreover, increasing levels of
NT-proBNP were related to the number of echocardio-
graphic abnormalities.
A recent systematic review concluded important
questions about the implementation of measuring
NT-proBNP in daily practice remain unsolved for the
diagnosis of cardiac dysfunction in elderly patients aged
75 and over from the general population [28]. The pre-
sent study confirms that low NT-proBNP levels are
most efficient in excluding echocardiographic abnormal-
ities in well-functioning nonagenarians. Possibly the
l e v e lo fN T - p r o B N Pm i g h tb eu s e dt oi n d i c a t ew h o
needs to be referred for further cardiovascular examina-
tion including echocardiography.
Some limitations should be acknowledged. First, we
were not able to correlate levels of NT-proBNP to echo-
c a r d i o g r a p h i cm e a s u r e m e n t sf o rt h ee n t i r ec o h o r t .S e e n
the small sample of well-functioning nonagenarians we
should be careful to generalize the findings of the present
study to the entire population of well-functioning nona-
genarians. Second, there was no available data on the
symptomatology of the participants. However, partici-
pants in the convenience sample only differed in func-
tional status, but had the same burden of cardio-vascular
comorbidities compared to the limited-functioning
elderly. Third, the fact the NT-proBNP levels were deter-
mined in 2006 after being frozen might have influenced
the absolute value, but it is unlikely that it has affected
the ranking. In addition, the applicability of current echo-
cardiographic cut-off values to nonagenarian subpopula-
tions may be debatable since the thresholds for normal
values are usually derived from younger subpopulations.
Finally, LVEF measured with biplane Simpson’s methods
was not systematically available in all patients.
Table 2 Echocardiographic Characteristics in Well-
Functioning Nonagenarians (n = 80)
Median (IQR) Normal value *
LV dimensions and
systolic function
LV EDD index (mm/m
2) 28 (24 – 31) ≤33
LV ESD index (mm/m
2) 17 (14 – 20) -
Interventricular septal
wall thickness (mm)
13 (10 – 14) ≤10
Posterior wall thickness
(mm)
11 (10 – 13) ≤10
LV Ejection fraction (%) 67 (60 – 77) ≥50
LV Mass index (g/m
2)
Men 132 (105 – 160) ≤149
Women 116 (96 – 145) ≤122
LV diastolic function
E/A ratio 0.7 (0.6 – 0.8) -
Indexed left atrial volume
(ml/m
2)
24 (14 – 33) ≤40
Estimated PAP (mmHg) 34 (30 - 37) ≤40
Valvular function Prevalence, n (%)
Mitral stenosis 0 (0)
Mitral regurgitation 58 (72)
Mild 20 (25)
Moderate 24 (30)
Severe 14 (17)
Aortic stenosis 14 (17)
Mild (mean ΔP<2 5
mmHg)
9 (11)
Moderate (mean ΔP
25 – 40 mmHg)
4 (5)
Severe (mean ΔP>
40 mmHg)
1 (1)
Aortic regurgitation 38 (48)
Mild 15 (19)
Moderate 17 (21)
Severe 6 (8)
Tricuspid stenosis 0 (0)
Tricuspid regurgitation 25 (31)
Mild 8 (10)
Moderate 4 (5)
Severe 13 (16)
Abbreviations: ΔP, pressure gradient; IQR, inter quartile range (25% - 75%);
EDD, end-diastolic diameter; ESD, end-systolic diameter; LV, left ventricular;
PAP, pulmonary artery pressure.
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Tertiles of NT-proBNP
* Adjusted B (95% CI)
1( n = 26) 2 (n = 27) 3 (n = 27) P for trend Model 1**, adjusted R
2 = 0.19
Model 2
£, adjusted R
2 = 0.35
P
LV dimensions and systolic function
LV EDD (mm) 42 (39 – 51) 47 (43 – 54) 51 (45 – 56) 0.003 –0.042 (–0.088 – 0.005) 0.081
LV ESD (mm) 27 (22 – 31) 28 (27 – 33) 32 (29 – 37) 0.002 0.034 (–0.030 – 0.099) 0.29
LV Ejection fraction (%) 69 (60 – 79) 67 (61 – 72) 67 (53 – 74) 0.24 0.006 (–0.017 – 0.030) 0.59
LV Mass index (g/m
2)
Men 213 (182 – 287) 236 (177 – 260) 268 (209 – 372) 0.068 0.003 (0.000 – 0.005) 0.045
Women 160 (142 – 190) 212 (169 – 242) 213 (160 – 260) 0.008
Left ventricular diastolic function
E/A 0.61 (0.51 – 0.70) 0.72 (0.61 – 0.78) 0.70 (0.56 – 1.1) 0.016 0.45 (0.026 – 0.87) 0.038
Left atrial volume (ml) 30.1 (22.1 – 40.0) 43.6 (25.6 – 55.3) 50.3 (33.8 – 73.6) 0.002 0.001 (–0.003 – 0.004) 0.67
Significant heart valvular disease
Mitral regurgitation ≥ moderate 4 (11%) 18 (47%) 16 (42%) 0.003 –0.046 (–0.14 – 0.045)
$ 0.32
Aortic regurgitation ≥ moderate 3 (13%) 8 (35%) 12 (52%) 0.014 0.11 (0.002 – 0.21)
$ 0.046
Any aortic stenosis 7 (50%) 3 (21%) 4 (29%) 0.25 –0.008 (–0.022 – 0.005)
$ 0.23
Estimated PAP (mmHg) 33 (26 – 36) 33 (29 – 37) 37 (33 – 40) 0.015 0.008 (–0.020 – 0.035)
£ 0.56
Abbreviations: EDD, end-diastolic diameter; ESD, end-systolic diameter; LV, left ventricular; PAP, pulmonary artery pressure.
*Echocardiographic parameters (median (IQR)) compared between gender-specific tertiles of NT-proBNP using the Jonckheere-Terpstra test (continuous variables) or the Chi-Square test with linear-by-linear
association (proportions). Median values of NT-proBNP levels were 143.2 pg/mL (IQR 103.3-220.7 pg/mL) in the first tertile, 380.6 pg/mL (IQR 326.2-499.4 pg/mL) in the second tertile and 1324.0 pg/mL (IQR 762.4-
2832.0 pg/mL) in the third tertile.
** Linear regression analysis with LogNT-proBNP as dependent variable and all echocardiographic measurements (except estimated PAP) as independent variables, adjusted for gender, BMI, renal function, anemia
and medications for heart failure (n = 56).
$ In the linear regression analysis the degree of mitral and aortic regurgitation were expressed as ordinal variables (1 to 4) and aortic stenosis was expressed as a continuous variable using the aortic valve peak
gradient.
£ Linear regression analysis with LogNT-proBNP as dependent variable and all echocardiographic measurements AND estimated PAP as independent variables, adjusted for gender, BMI, renal function, anemia and
medications for heart failure (n = 37).
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9Conclusions
In conclusion, this study showed NT-proBNP is related
to a wide variety of functional and structural echocardio-
graphic abnormalities in well-functioning nonagenarians.
Furthermore, low values of NT-proBNP were able to
exclude echocardiographic abnormalities and could be
used to identify nonagenarians that need to be referred
for further cardiovascular examination.
Table 4 Test Characteristics for NT-proBNP Levels (Cut-off 269.5 pg/mL) for Detecting Structural and Functional
Cardiac Abnormalities in Nonagenarians
Prevalence n
(%)
AUC (95% CI) Sens.
(%)
Spec.
(%)
PPV
(%)
NPV
(%)
Abnormal LV dimensions (LVEDD index ≥33 mm/m
2 or LV hypertrophy) and/or
LV systolic dysfunction
38 (48) 0.75 (0.64–0.85) 84 48 59 77*
LV systolic dysfunction (EF < 50) 7 (9) 0.67 (0.42–0.92) 71 33 9 92*
Indexed left atrial volume ≥ 40 ml/m
2 12 (15) 0.74 (0.60–0.88) 92 36 21 96
£
Severe valvular heart disease
# 21 (26) 0.71 (0.58–0.84) 90 41 35 92
$
PAP ≥ 40 mmHg 10 (13) 0.85 (0.72–0.98) 100 35 28 100
Severe valvular heart disease and/or LV systolic dysfunction (EF < 50) 25 (31) 0.68 (0.55–0.81) 84 40 39 85
$
Any severe echocardiographic abnormality 50 (63) 0.77 (0.66–0.88) 82 57 76 65
$
Area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) calculated for an NT-proBNP cut-off value
of 269.5 pg/mL.
Abbreviations: EDD, end-diastolic diameter; LV, left ventricular; EF: ejection fraction; PAP, pulmonary artery pressure; CI, confidence intervals.
An NT-proBNP cut-off value of 130 pg/mL (*), 236 pg/mL (
£) and 61 pg/mL (
$) increased the NPV to 100%.
# Severe mitral or aortic stenosis, severe mitral regurgitation and severe aortic regurgitation.
Figure 1 Relationship between LogNT-proBNP Level and Number of Cardiac Abnormalities at Age 90. Error bars in these box-and-
whisker plots show the mean and 95% confidence intervals of LogNT-proBNP at age 90 related to total amount of cardiac abnormalities,
including LVEDD > 33 mm/m
2, EF < 50%, indexed left atrial volume >40 ml/m
2, LV hypertrophy (men > 149 g/m
2, women > 122 g/m
2),
presence of severe mitral regurgitation, presence of severe aortic regurgitation, presence of severe aortic stenosis or PAP ≥ 40 mmHg. * by
ANOVA.
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pressure.
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